JP2005509596A - フェノフィブラートのナノ粒子製剤 - Google Patents
フェノフィブラートのナノ粒子製剤 Download PDFInfo
- Publication number
- JP2005509596A JP2005509596A JP2003518484A JP2003518484A JP2005509596A JP 2005509596 A JP2005509596 A JP 2005509596A JP 2003518484 A JP2003518484 A JP 2003518484A JP 2003518484 A JP2003518484 A JP 2003518484A JP 2005509596 A JP2005509596 A JP 2005509596A
- Authority
- JP
- Japan
- Prior art keywords
- nanosuspension
- nanoparticles
- fibrate
- vitamin
- fenofibrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
表1は本発明のフェノフィブラートの代表的は製剤を示す。
ビタミンE TPGSを使用したナノ懸濁液の調製
A)スラリーの調製:100g
フェノフィブラート:10.00g
ビタミンE TPGS:0.50g
注射用水:89.50g
実施例1(A)で得られた懸濁液を高圧ピストンギャップホモジナイザーに通してナノ懸濁液を得た。これはAvestin C50を用いて調製した。均質化圧は長さ11.34mmの「鋭い端」設計のバルブを用いて240分間1500バールに設定した。均質化中、薬物粒子はキャビテーション効果およびせん断力のために崩壊し、ナノ粒子を形成した。レーザー回折計(Coulter LS 230)で測定した粒子径(ミクロン、容積%)は次の結果を示した(3回測定した)。
ナノ乳濁液とナノ懸濁液の混合
A)スラリーの調製:100g
フェノフィブラート:10,00g
ビタミンE TPGS:0.50g
注射用水:89.50g
実施例2(A)で得られた懸濁液を高圧ピストンギャップホモジナイザーに通してナノ懸濁液を得た。これはAvestin C50を用いて調製した。均質化圧は長さ11.34mmの「鋭い端」設計のバルブを用いて240分間1500バールに設定した。均質化中、薬物粒子はキャビテーション効果およびせん断力のために崩壊し、ナノ粒子を形成した。レーザー回折計(Coulter LS 230)で測定した粒子径(ミクロン、容積%)は次の結果を示した(3回測定した)。
ピーナッツ油:4.00g
Span20:0.80g
注射用水:35.20g
実施例2(C)で得られた乳濁液を高圧ピストンギャップホモジナイザーに通してナノ乳濁液を得た。製剤はAvestin C50を用いて調製した。均質化圧は長さ11.34mmの「鋭い端」設計のバルブを用いて30分間500バールに設定した。均質化中、脂質の液滴はキャビテーション効果およびせん断力のために崩壊し、固体のナノ粒子を形成した。レーザー回折計(Coulter LS 230)で測定した粒子径(ミクロン、容積%)は次の結果を示した(3回測定した)。
実施例2(B)で得られたナノ懸濁液(10.0g)と実施例2(D)で得られたナノ乳濁液(0.5g)との混合を磁気攪拌(500rpmで5分間)下で行った。
ナノ乳濁液およびナノ懸濁液の混合
A)乳濁液の調製:40g
ピーナッツ油:4.00g
Span20:0.80g
フェノフィブラート:0.20g
注射用水:35.20g
実施例3(A)で得られた乳濁液を高圧ピストンギャップホモジナイザーに通してナノ乳濁液を得た。製剤はAvestin C50を用いて調製した。均質化圧は長さ11.34mmの「鋭い端」設計のバルブを用いて30分間500バールに設定した。均質化中、脂質の液滴はキャビテーション効果およびせん断力のために崩壊し、固体の脂質のナノ粒子を形成した。レーザー回折計(Coulter LS 230)で測定した粒子径(ミクロン、容積%)は次の結果を示した(3回測定した)。
凍結乾燥フェノフィブラートナノ懸濁液
フェノフィブラートナノ懸濁液を5% w/w トレハロースを「担体」として用いて凍結乾燥した。
フェノフィブラート:10.00g
ビタミンE TPGS:0.50g
注射用水:89.50g
得られた懸濁液を高圧ピストンギャップホモジナイザーに通してナノ懸濁液を得た。製剤9420-050/13ANはAvestin C50を用いて調製した。均質化圧は長さ11.34mm長さの「鋭い端」設計のバルブを用いて300分間1500バールに設定した。均質化中、薬物粒子はキャビテーション効果およびせん断力のために崩壊し、ナノ粒子を形成した。レーザー回折計(Coulter LS 230)で測定した粒子径(ミクロン、容積%)は次の結果を示した:3回測定した。
フェノフィブラートナノ懸濁液をゆっくり攪拌しながら、7.5gのトレハロース加えた。各2mlのトレハロース/フェノフィブラートのナノ懸濁液の6つの試料を凍結乾燥に供した。凍結乾燥プロセスパラメーターを次のように設定した。
凍結乾燥温度:-35℃
乾燥温度:+5℃
圧力:0.940mバール
プロセス時間:凍結=1時間30分、乾燥=18時間30分
Claims (14)
- フィブラートおよびビタミンE TPGSを含むナノ粒子であって、光子相関分光法で測定して約100nmから約900nmの範囲の平均径を有するナノ粒子。
- 請求項1記載のフィブラートおよびビタミンE TPGSを含むナノ粒子であって、光子相関分光法で測定して約400nmから約600nmの範囲の平均径を有するナノ粒子。
- ナノ懸濁液の形態における請求項1または請求項2記載のナノ粒子フィブラート。
- 水性ナノ懸濁液である、請求項3記載のナノ懸濁液。
- 追加の安定剤に関連した、請求項3記載のナノ粒子または請求項4記載のナノ懸濁液。
- フィブラートがフェノフィブラートである、請求項1、3または5のいずれか一項記載のナノ粒子または請求項4記載のナノ懸濁液。
- 請求項1から6のいずれか一項記載のナノ粒子フィブラートを含む薬学的製剤。
- 油のナノ液滴を含むナノ粒子フィブラート製剤。
- 油のナノ液滴において、ナノ粒子として分散した活性物質の一部と、溶解した活性物質の一部とを含む、ナノ粒子のフィブラート製剤。
- フィブラートおよびビタミンE TPGSを含むナノ粒子の調製法であって、ビタミンE TPGSは粗分散液中に存在するかまたはキャビテーションプロセスの前に導入するかのいずれかであり、フィブラートの粗分散液がキャビテーションを受ける段階を含む、調整法。
- 高圧ピストンギャップホモジナイザーを用いて実施される、請求項7記載の方法。
- 医薬品に使用される、請求項1から3または5のいずれか一項記載のナノ粒子、または請求項4記載のナノ懸濁液。
- 動脈硬化、肥満、心筋梗塞または高血圧の治療用の医薬品の調製における、請求項1から3または5のいずれか一項記載のナノ粒子、または請求項4記載のナノ懸濁液の使用。
- 治療を必要とする患者に、請求項1から3または5のいずれか一項記載のナノ粒子フィブラートまたは請求項4記載のナノ懸濁液の薬学的製剤を治療量投与する段階を含む、高脂血症の治療法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0119480.2 | 2001-08-09 | ||
GBGB0119480.2A GB0119480D0 (en) | 2001-08-09 | 2001-08-09 | Novel compositions |
PCT/GB2002/003687 WO2003013474A1 (en) | 2001-08-09 | 2002-08-09 | Nanoparticulate formulations of fenofibrate |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2005509596A true JP2005509596A (ja) | 2005-04-14 |
JP2005509596A6 JP2005509596A6 (ja) | 2005-08-04 |
JP2005509596A5 JP2005509596A5 (ja) | 2006-01-05 |
JP4721640B2 JP4721640B2 (ja) | 2011-07-13 |
Family
ID=9920132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003518484A Expired - Fee Related JP4721640B2 (ja) | 2001-08-09 | 2002-08-09 | フェノフィブラートのナノ粒子製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8663693B2 (ja) |
EP (1) | EP1414410B1 (ja) |
JP (1) | JP4721640B2 (ja) |
AT (1) | ATE422155T1 (ja) |
DE (1) | DE60231082D1 (ja) |
ES (1) | ES2321912T3 (ja) |
GB (1) | GB0119480D0 (ja) |
WO (1) | WO2003013474A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007119456A (ja) * | 2005-09-30 | 2007-05-17 | Toyama Chem Co Ltd | 難溶性薬物のナノ微粒子を含有する水性懸濁液剤 |
JP2011516421A (ja) * | 2008-03-28 | 2011-05-26 | エラン ファーマ インターナショナル,リミティド | フェノフィブラート剤形 |
JP2012516346A (ja) * | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | ピリドピリミジノンの経口用固体製剤 |
JP2013527845A (ja) * | 2010-04-30 | 2013-07-04 | エイチ アール ディー コーポレーション | ドラッグデリバリーにおける高せん断の利用 |
US8888736B2 (en) | 2010-04-30 | 2014-11-18 | H R D Corporation | High shear application in medical therapy |
JP2015523400A (ja) * | 2012-07-27 | 2015-08-13 | バント,アントニウス,マルティヌス ガステーブ | 排出阻害剤およびこれを用いる治療法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
CA2488499C (en) * | 2002-06-10 | 2013-03-19 | Elan Pharma International Ltd. | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions |
JP2007502331A (ja) * | 2003-05-29 | 2007-02-08 | グリュコン テクノロジーズ グループ エルエルシー | (−)−ヒドロキシクエン酸を安定して制御送達するための方法および組成物 |
CN101031284A (zh) * | 2004-09-30 | 2007-09-05 | 伊斯曼化学公司 | 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途 |
US20070128289A1 (en) * | 2005-12-07 | 2007-06-07 | Zhao Jonathon Z | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases |
AU2007265452A1 (en) * | 2006-06-26 | 2008-01-03 | Mutual Pharmaceutical Company, Inc. | Active agent formulations, methods of making, and methods of use |
US20080161594A1 (en) * | 2006-12-29 | 2008-07-03 | Industrial Technology Research Institute | Method for fabricating nanoparticles containing fenofibrate |
US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
JP5711671B2 (ja) * | 2009-02-23 | 2015-05-07 | ナノルクス、インコーポレイテッドNanorx,Inc. | ポリコサノールナノ粒子 |
US9034383B2 (en) | 2010-08-23 | 2015-05-19 | NanoRx, Inc. | Policosanol nanoparticles |
GB201118181D0 (en) * | 2011-10-21 | 2011-12-07 | Jagotec Ag | Pharmaceutical compositions |
US9962404B2 (en) * | 2012-09-21 | 2018-05-08 | Reoxcyn Innovation Group, Llc | Cell for electrolyzing a liquid |
EP2961433A4 (en) * | 2013-02-28 | 2016-11-30 | Univ Ramot | PEPTIDE-BASED HYDROGEL PARTICLES AND USES THEREOF |
CN105218370A (zh) * | 2014-06-10 | 2016-01-06 | 无锡康福特药物科技有限公司 | 一种贝特类降脂药物的超微粉体及其制备方法 |
EP3928772B1 (en) | 2020-06-26 | 2024-06-19 | Algiax Pharmaceuticals GmbH | Nanoparticulate composition |
WO2022094054A1 (en) * | 2020-10-28 | 2022-05-05 | Mydecine Innovations Group Inc. | Novel fungal compound formulations and their therapeutic methods of use |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029300A1 (en) * | 1997-12-10 | 1999-06-17 | Rtp Pharma Inc. | Self-emulsifying fenofibrate formulations |
WO1999048477A1 (fr) * | 1998-03-23 | 1999-09-30 | Laboratoire Theramex | Composition hormonale topique a effet systemique |
WO2000076482A1 (en) * | 1999-06-11 | 2000-12-21 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
WO2001015688A1 (en) * | 1999-09-02 | 2001-03-08 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
WO2001021154A2 (en) * | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2627696B1 (fr) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
US5545628A (en) | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
FR2730231B1 (fr) | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
US5919776A (en) * | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
DE19800250A1 (de) | 1997-01-13 | 1998-08-06 | Winter Cvd Technik Gmbh | Schleifkörper |
FR2758459B1 (fr) | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
FR2758461A1 (fr) | 1997-01-17 | 1998-07-24 | Pharma Pass | Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation |
US5891845A (en) | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
FR2774591B1 (fr) | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
JP4693238B2 (ja) | 1998-06-19 | 2011-06-01 | オバン・エナジー・リミテッド | 水に溶けない化合物のサブミクロン粒子を生成させる方法 |
FR2783421B1 (fr) | 1998-09-17 | 2000-11-24 | Cll Pharma | Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications |
US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
NZ511792A (en) | 1998-11-20 | 2003-08-29 | Skyepharma Canada Inc | Dispersible phospholipid stabilized microparticles |
AU767737B2 (en) | 1998-11-20 | 2003-11-20 | Skyepharma Canada Inc. | Method of preparing stable suspensions of insoluble microparticles |
US6180138B1 (en) | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6270806B1 (en) | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
FR2795961B1 (fr) | 1999-07-09 | 2004-05-28 | Ethypharm Lab Prod Ethiques | Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation |
CN1129214C (zh) | 1999-11-17 | 2003-11-26 | 株式会社爱德万测试 | Ic插座及ic测试装置 |
FR2803203B1 (fr) * | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
-
2001
- 2001-08-09 GB GBGB0119480.2A patent/GB0119480D0/en not_active Ceased
-
2002
- 2002-08-09 DE DE60231082T patent/DE60231082D1/de not_active Expired - Lifetime
- 2002-08-09 AT AT02749130T patent/ATE422155T1/de not_active IP Right Cessation
- 2002-08-09 EP EP02749130A patent/EP1414410B1/en not_active Expired - Lifetime
- 2002-08-09 ES ES02749130T patent/ES2321912T3/es not_active Expired - Lifetime
- 2002-08-09 JP JP2003518484A patent/JP4721640B2/ja not_active Expired - Fee Related
- 2002-08-09 US US10/486,299 patent/US8663693B2/en not_active Expired - Fee Related
- 2002-08-09 WO PCT/GB2002/003687 patent/WO2003013474A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029300A1 (en) * | 1997-12-10 | 1999-06-17 | Rtp Pharma Inc. | Self-emulsifying fenofibrate formulations |
WO1999048477A1 (fr) * | 1998-03-23 | 1999-09-30 | Laboratoire Theramex | Composition hormonale topique a effet systemique |
WO2000076482A1 (en) * | 1999-06-11 | 2000-12-21 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
WO2001015688A1 (en) * | 1999-09-02 | 2001-03-08 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
WO2001021154A2 (en) * | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007119456A (ja) * | 2005-09-30 | 2007-05-17 | Toyama Chem Co Ltd | 難溶性薬物のナノ微粒子を含有する水性懸濁液剤 |
JP2011516421A (ja) * | 2008-03-28 | 2011-05-26 | エラン ファーマ インターナショナル,リミティド | フェノフィブラート剤形 |
JP2012516346A (ja) * | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | ピリドピリミジノンの経口用固体製剤 |
JP2013527845A (ja) * | 2010-04-30 | 2013-07-04 | エイチ アール ディー コーポレーション | ドラッグデリバリーにおける高せん断の利用 |
US8888736B2 (en) | 2010-04-30 | 2014-11-18 | H R D Corporation | High shear application in medical therapy |
US8888735B2 (en) | 2010-04-30 | 2014-11-18 | H R D Corporation | High shear application in medical therapy |
US9381138B2 (en) | 2010-04-30 | 2016-07-05 | H R D Corporation | High shear application in medical therapy |
JP2015523400A (ja) * | 2012-07-27 | 2015-08-13 | バント,アントニウス,マルティヌス ガステーブ | 排出阻害剤およびこれを用いる治療法 |
Also Published As
Publication number | Publication date |
---|---|
EP1414410A1 (en) | 2004-05-06 |
EP1414410B1 (en) | 2009-02-04 |
US8663693B2 (en) | 2014-03-04 |
WO2003013474A1 (en) | 2003-02-20 |
JP4721640B2 (ja) | 2011-07-13 |
ATE422155T1 (de) | 2009-02-15 |
DE60231082D1 (de) | 2009-03-19 |
ES2321912T3 (es) | 2009-06-15 |
GB0119480D0 (en) | 2001-10-03 |
US20050095297A1 (en) | 2005-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4721640B2 (ja) | フェノフィブラートのナノ粒子製剤 | |
JP2005509596A6 (ja) | フェノフィブラートのナノ粒子製剤 | |
EP1320362B1 (en) | Stabilised fibrate microparticles | |
US6368620B2 (en) | Formulations comprising lipid-regulating agents | |
CA2802767C (en) | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine | |
CA2746887C (en) | Methods for enhancing the release and absorption of water insoluble active agents | |
EP1970050B1 (en) | Butylphthalide intravenous emulsion and application thereof | |
Choi et al. | Effects of different physicochemical characteristics and supersaturation principle of solidified SNEDDS and surface-modified microspheres on the bioavailability of carvedilol | |
Jaiswal et al. | Bioavailability enhancdement of poorly soluble drugs by smedds: a review | |
JP2010241820A (ja) | 保護被膜を有する再分散性超微粒状フィルムマトリックス | |
WO2001080828A2 (en) | Improved water-insoluble drug particle process | |
AU2001257115A1 (en) | Improved water-insoluble drug particle process | |
FR2803203A1 (fr) | Nouvelles formulations galeniques du fenofibrate | |
Mundada et al. | Submicron emulsions and their applications in oral delivery | |
US7255877B2 (en) | Fenofibrate microparticles | |
Meola et al. | Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro | |
US7666307B2 (en) | Particle size reduction of bioactive compounds | |
JP5792300B2 (ja) | 6’−フルオロ−(N−メチル−又はN,N−ジメチル−)−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンを含む医薬剤形 | |
Poovi et al. | Solid lipid nanoparticles and nanostructured lipid carriers: a review of the effect of physicochemical formulation factors in the optimization process, different preparation technique, characterization, and toxicity | |
JP2008518931A (ja) | 自発的に分散可能な医薬組成物 | |
Kazi | Lipid‐based nano‐delivery for oral administration of poorly water soluble drugs (PWSDs): design, optimization and in-vitro assessment | |
Sri et al. | A review on SEDDS and Solid SEDDS: an emerging dosage forms for poorly soluble drugs | |
Nandal et al. | Novel Approaches of Self Emulsifying Drug Delivery Systems and Recent Patents: A Comprehensive Review | |
AU2006201100B2 (en) | Surface modified particulate compositions of biologically active substances | |
Dhawale et al. | Self-Emulsifying Drug Delivery System a Tool for Enhancement of Solubility: A Critical Review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050801 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050801 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20051019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090803 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100610 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110309 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110405 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140415 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |